home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

GlycoMimetics, Inc. - Common Stock (NQ:GLYC)

0.1570 UNCHANGED

Last Price Updated: 4:00 PM EDT, Jun 13, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about GlycoMimetics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

A Preview Of GlycoMimetics's Earnings ↗

March 02, 2022

GlycoMimetics (NASDAQ:GLYC) is set to give its latest quarterly earnings report on Thursday, 2022-03-03. Here's what investors need to know before the announcement. Analysts...

Via Benzinga

GlycoMimetics to Report Fourth Quarter and 2021 Year-End Financial Results on March 3, 2022

February 25, 2022

From GlycoMimetics, Inc.

Via Business Wire

GlycoMimetics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

February 23, 2022

From GlycoMimetics, Inc.

Via Business Wire

GlycoMimetics Appoints Bruce Johnson Senior Vice President and Chief Commercial Officer

February 23, 2022

From GlycoMimetics, Inc.

Via Business Wire

The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline ↗

August 18, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 17) AbbVie Inc. (NYSE: ABBV)...

Via Benzinga

The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business ↗

August 17, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 16) Bio-Rad Laboratories, Inc...

Via Benzinga

The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO ↗

August 05, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 4) Absci, CORP (NASDAQ: ABSI) (...

Via Benzinga

Two GlycoMimetics Posters at 63rd ASH Annual Meeting Highlight Potential of GMI-1359, a Dual Antagonist of CXCR4 and E-selectin

December 13, 2021

From GlycoMimetics, Inc.

Via Business Wire

NCI-Sponsored Trial of Uproleselan in Older, Newly Diagnosed AML Patients Fit for Intensive Chemotherapy Completes Enrollment of Phase 2 Portion Ahead of Schedule

December 06, 2021

From GlycoMimetics, Inc.

Via Business Wire

Apollomics Inc. Doses First Patient in Phase 3 Clinical Trial in China of GlycoMimetics’ Uproleselan for the Treatment of AML

November 23, 2021

From GlycoMimetics, Inc.

Via Business Wire

GlycoMimetics Appoints Regulatory Veteran Lisa DeLuca as Vice President, Regulatory Affairs

November 22, 2021

From GlycoMimetics, Inc.

Via Business Wire

GlycoMimetics Completes Enrollment of Phase 3 Registration Trial Evaluating Lead Candidate Uproleselan in Patients with Relapsed /Refractory Acute Myeloid Leukemia (AML)

November 15, 2021

From GlycoMimetics, Inc.

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For November 12, 2021 ↗

November 12, 2021

Upgrades For Blink Charging Co (NASDAQ:

Via Benzinga

18 Stocks Moving In Friday's Pre-Market Session ↗

November 12, 2021

Gainers NuZee, Inc. (NASDAQ: NUZE) rose 30.3% to $6.89 in pre-market trading after jumping around 165% on Thursday. NuZee manufacturing partner, Cuvee Coffee, reported an...

Via Benzinga

GlycoMimetics GMI-1359 Data Selected for Presentation at 63rd American Society of Hematology (ASH) Annual Meeting and Exposition

November 11, 2021

From GlycoMimetics, Inc.

Via Business Wire

GlycoMimetics to Present at Two Upcoming Healthcare Investor Conferences

November 09, 2021

From GlycoMimetics, Inc.

Via Business Wire

GlycoMimetics, inc (GLYC) Q3 2021 Earnings Call Transcript ↗

November 02, 2021

GLYC earnings call for the period ending September 30, 2021.

Via The Motley Fool

Topics Earnings

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

November 02, 2021

Gainers Bone Biologics (NASDAQ:BBLG) shares rose 33.57% to $7.32 during Tuesday's pre-market session. The company's market cap stands at $224.5 million. Artelo...

Via Benzinga

GlycoMimetics Reports Highlights and Financial Results for Third Quarter 2021

November 02, 2021

From GlycoMimetics, Inc.

Via Business Wire

GlycoMimetics to Report Third Quarter Financial Results on November 2, 2021

October 26, 2021

From GlycoMimetics, Inc.

Via Business Wire

GlycoMimetics' Lead Candidate Data Published In An Online Journal ↗

September 24, 2021

GlycoMimetics Inc (NASDAQ: GLYC) has announced that efficacy and safety data from a Phase 1/2 study of uproleselan were published online in the journal BLOOD. In...

Via Benzinga

Efficacy and Safety Data for GlycoMimetics’ Lead Investigational Drug Uproleselan Published in BLOOD

September 23, 2021

From GlycoMimetics, Inc.

Via Business Wire

GlycoMimetics to Present at Upcoming H.C. Wainwright & Co Annual Global Investment Virtual Conference

September 08, 2021

From GlycoMimetics, Inc.

Via Business Wire

GlycoMimetics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

August 09, 2021

From GlycoMimetics, Inc.

Via Business Wire

The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen's Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data ↗

August 20, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 19) Alkermes plc (NASDAQ: ALKS...

Via Benzinga

GlycoMimetics, inc (GLYC) Q2 2021 Earnings Call Transcript ↗

August 07, 2021

GLYC earnings call for the period ending June 30, 2021.

Via The Motley Fool

Topics Earnings

Stocks That Hit 52-Week Lows On Thursday ↗

August 05, 2021

During Thursday's morning session, 77 companies made new 52-week lows. Areas of Interest: The largest company in terms of market cap to set a new 52-week low...

Via Benzinga

The Daily Biotech Pulse: Dicerna Slips On Data, Novavax Tightlipped On US Vaccine Approval, Adagio IPO ↗

August 06, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 5) Alkermes plc (NASDAQ: ALKS)...

Via Benzinga

GlycoMimetics Reports Highlights and Financial Results for Second Quarter 2021

August 05, 2021

From GlycoMimetics, Inc.

Via Business Wire

GlycoMimetics Names Harout Semerjian as New Chief Executive Officer to Succeed Retiring CEO Rachel King

August 04, 2021

From GlycoMimetics, Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com